Insight Molecular Diagnostics Inc. Stockholders Equity

• Insight Molecular Diagnostics Inc. showed a decrease of -156.3% in Stockholders Equity from 2024 to 2025.
• This data is from Insight Molecular Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $6.90 million | Q2 2016: $4.47 million | Q3 2016: $12.68 million | Q1 2017: $8.77 million | Q2 2017: $5.64 million | Q3 2017: $8.05 million | Q1 2018: $9.02 million | Q2 2018: $6.85 million | Q3 2018: $7.52 million | Q1 2019: $38.19 million | Q2 2019: $33.51 million | Q3 2019: $29.34 million | Q1 2020: $36.63 million | Q2 2020: $39.59 million | Q3 2020: $34.64 million | Q1 2021: $106.63 million | Q2 2021: $102.67 million | Q3 2021: $99.35 million | Q1 2022: $56.97 million | Q2 2022: $83.24 million | Q3 2022: $76.86 million | Q1 2023: $37.93 million | Q2 2023: $43.60 million | Q3 2023: $36.14 million | Q1 2024: $11.59 million | Q2 2024: $22.70 million | Q3 2024: $9.71 million | Q1 2025: $10.22 million | Q2 2025: $1.10 million | Q3 2025: -$9.20 million.
• Over the full 13 years of available data (2013 to 2025), Insight Molecular Diagnostics Inc.'s Stockholders Equity has declined by 970.4%.
• Historical annual values: Fiscal year 2025: -$31.46 million | Fiscal year 2024: -$12.27 million | Fiscal year 2023: $20.47 million | Fiscal year 2022: $34.29 million | Fiscal year 2021: $65.22 million | Fiscal year 2020: $33.48 million | Fiscal year 2019: $30.84 million | Fiscal year 2018: $3.42 million | Fiscal year 2017: $4.40 million | Fiscal year 2016: $9.86 million | Fiscal year 2015: $10.42 million | Fiscal year 2014: -$1.07 million | Fiscal year 2013: $3.62 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026